MET has also been implicated in enhancing cytotoxic effects of other chemotherapeutics in cancer cell lines of different origins, such as bladder cancer, squamous cell carcinoma and head and neck cancer, albeit with varying efficacy, greatly depending on cell type, the chemotherapeutic agent and applied concentrations (Landgraf et al. 2019; Michalska et al. 2018; Shi et al. 2019). This evidence concerns the gene MET and urinary bladder cancer.